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PD‑L1 immune checkpoints and current
methodologies for their development: a review
Chang Liu* , Navindra P. Seeram and Hang Ma*

Abstract
Programmed death-1/programmed death ligand-1 (PD-1/PD-L1) based immunotherapy is a revolutionary cancer
therapy with great clinical success. The majority of clinically used PD-1/PD-L1 inhibitors are monoclonal antibodies
but their applications are limited due to their poor oral bioavailability and immune-related adverse effects (irAEs). In
contrast, several small molecule inhibitors against PD-1/PD-L1 immune checkpoints show promising blockage effects
on PD-1/PD-L1 interactions without irAEs. However, proper analytical methods and bioassays are required to effectively screen small molecule derived PD-1/PD-L1 inhibitors. Herein, we summarize the biophysical and biochemical
assays currently employed for the measurements of binding capacities, molecular interactions, and blocking effects of
small molecule inhibitors on PD-1/PD-L1. In addition, the discovery of natural products based PD-1/PD-L1 antagonists
utilizing these screening assays are reviewed. Potential pitfalls for obtaining false leading compounds as PD-1/PD-L1
inhibitors by using certain binding bioassays are also discussed in this review.
Keywords: Cancer, Immunotherapy, PD-1/PD-L1, Natural products, Small molecules
Introduction
Tumors can bypass immune surveillance by exploiting
immune-escape mechanisms including the induction of
an immunosuppressive microenvironment and suppression of effector T cells’ function in the tumor microenvironment [1, 2]. Cancer immunotherapy is designed to
re-activate anti-tumor immune response and enhance
its effects, thereby restoring tumor immune suppression
[3–5]. Activating T cell-mediated anti-tumor responses
is one of the most effective strategies on the basis of the
regulation of immune checkpoints, which are crucial
receptors for preventing autoimmunity, protecting the
host from tissue damage, and regulating self-tolerance
[6–8].
*Correspondence: hichang813@uri.edu; hang_ma@uri.edu
Bioactive Botanical Research Laboratory, Department of Biomedical
and Pharmaceutical Sciences, College of Pharmacy, University of Rhode
Island, Avedisian Hall Lab 440, 7 Greenhouse Road, Kingston, RI 02881,
USA

T cell-mediated cancer immunotherapy is a breakthrough since its discovery [9, 10]. The activation of
cancer-specific T cells eliminates cancer cells by the recognition of tumor-specific antigens [10, 11]. T cell-mediated cancer immunotherapy consists of three steps. First,
antigens are presented by antigen-presenting cells (APCs)
such as dendritic cells (DCs) as antigenic peptides, which
are recognized by the T-cell receptor (TCR; Signal 1) [12].
The secondary signal is then delivered when B7 proteins
(CD80 and CD86) on the APCs engage with CD28 on
the T cells, leading to the activation of T cells [13]. Subsequently, the activated cancer-specific T cells enter into
the tumor sites and recognize tumor-specific antigens
thereby destroying the cancer cells [13]. However, in the
tumor microenvironment, cancer cells highly express coinhibitory protein ligands including CD80/86 and programmed death-ligand 1 (PD-L1) [14–16]. Co-inhibitory
proteins including cytotoxic T-lymphocyte-associated
protein 4 (CLTA-4) and programmed cell death protein 1
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(PD-1) are activated by binding to their ligands expressed
on cancer cells [17–19]. Consequently, cancer-specific T
cell activation is prevented so the cancer cells can escape
from immune surveillance. Therefore, blockage of the
co-inhibitory signals on the T cells and the activation of
cancer-specific T cells represent a promising strategy in
cancer immunotherapy.
PD-1 is a co-inhibitory receptor mainly expressed on
the surface of T cells [20]. PD-1’s primary function is
to suppress the T cells’ activity by the regulation of the
TCR signaling cascade [21–23]. High PD-L1 expression
in tumor microenvironment is frequently observed in
many types of cancers including Hodgkin’s lymphoma,
breast cancer, renal cell carcinoma, melanoma, lung cancer, gastric cancer, and hepatoma [24–30]. In the tumor
microenvironment, PD-L1 binds to PD-1 leading to T
cell dysfunction, whereas blockage of their interactions
recovers the T cell’s activity of destroying tumor cells [31,
32]. Previous studies reported that the blockage of the
PD-L1/PD-1 interactions is a promising strategy for cancer immunotherapy [18, 32, 33]. Blockage of PD-L1/PD-1
interactions can terminate the PD-1 mediated-signaling
pathways and reactivate the T cell-mediated anti-tumor
responses by promoting T cell proliferation and enhancing effector T cell’s function [32, 34]. Clinical studies
reported that the blockade of PD-1/PD-L1 interactions
can boost T cell-mediated antitumor responses, generate
durable clinical responses, and prolong patient survival
rate [17, 35]. To date, monoclonal antibodies (mAbs)
targeting PD-1 (e.g. Cemiplimab, Nivolumab, and Pembrolizumab) or PD-L1 (e.g. Durvalumab, Avelumab, and
Atezolizumab) are approved by the United States FDA
for the treatment of a series of malignancies [16, 36–38].
Although these mAbs exhibit promising therapeutic
effectiveness in clinical studies, restrictions including
immune-related adverse effects, immunogenicity, and
high costs are imposed for the clinical utilization of antibody-based immune checkpoint inhibitors [15, 17, 39,
40]. In addition, these mAbs exert limited permeability
in the tumor tissues due to their large size [41, 42]. Their
relatively long half-life increases the difficulty in drug
elimination, which may lead to severe side effects. Alternatively, small molecule inhibitors may possess favorable
tumor penetration and oral bioavailability [42]. Moreover, small molecule inhibitors may exert other advantages
such as fewer side effects, are easier self-administered,
have shorter biological half-life, and are less expensive
than mAbs, which have attracted great attention in pharmaceutical industries. However, most small molecule
inhibitors against PD-1/PD-L1 are still in the early drug
development stage with a focus on preclinical studies.
Currently, preclinical studies have demonstrated that
small molecule inhibitors can exhibit superior capacities
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to inhibit tumor growth with favorable biosafety as
compared to mAbs [42]. Among these small molecule
inhibitors, several synthetic small molecules from Bristol Myers Squibb (e.g. BMS1166 and BMS202) and Curis
Inc. (i.e. CA-170) exhibit promising tumor suppression
effects in interrupting the PD-1/PD-L1 interactions [43,
44]. However, there are relatively fewer reports and preclinical studies on natural product-derived small molecule inhibitors.
Bioassays are crucial to assess the blockage effects of
small molecules against the PD-1/PD-L1 interactions
as well as their binding affinities and how their biological functions impact PD-1/PD-L1. Currently, bioassays
to determine the potency of small molecule inhibitors
against PD-1/PD-L1 include biophysical and biochemical assays, in vitro cell-based assays, and in vivo tumor
xenograft model [45–47]. Biophysical and biochemical assays are used for the assessment of small molecule
binding profiles and for the screening of potential inhibitors. In vitro cell-based assays and in vivo tumor xenograft models can evaluate small molecules’ functional
effects on PD-1/PD-L1. In addition, due to the encouraging promise of small molecule inhibitors against PD-1/
PD-L1, researchers have developed various robust and
effective assays for screening PD-1/PD-L1 inhibitors.
Herein, PD-1/PD-L1 immune checkpoints and their
interactions are summarized. In addition, natural product-based small molecule inhibitors against PD-1/PD-L1
and current methodologies employed for their development are reviewed. The potential pitfalls and future of
small molecule inhibitors against PD-1/PD-L1 are also
examined.

PD‑1/PD‑L1 and their interactions
PD-1 (CD279) is a transmembrane protein consisting
of 288 amino acids belonging to the CD28 superfamily
[28]. The structure of PD-1 consists of an extracellular
IgV domain connected to a transmembrane region and
an intracellular tail, which contains two phosphorylation
sites on two motifs including the immunoreceptor tyrosine-based switch motif (ITSM) and immunoreceptor
tyrosine-based inhibitory motif (ITIM) [28]. Immunoglobulin (Ig)-like extracellular domain is responsible for
engagement and signaling transduction to intracellular
domain. After engagement with PD-L1 (CD274; B7-H1)
and PD-L2 (CD273; B7-DC), PD-1 delivers ‘negative’ signals to T cells to suppress T cell’s activity. In addition,
PD-1 is expressed on the surface of regulatory T cells,
activated B cells, monocytes, macrophages, DCs, and
natural killer cells [48]. However, the mechanisms of the
regulation of PD-1 signaling pathways on these cells are
unclear.
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PD-1 expression is dynamically changed and intricately
regulated by host immune responses [49, 50]. Usually, it
is expressed at a low, basal level in resting naive T cells
(Th0 cells) to maintain immunological tolerance. However, PD-1 is upregulated by a series of immune cells
including CD4 and CD8 T cells, B cells, macrophages,
and DCs in response to initial immune stimuli [51]. PD-1
is often down-regulated when the antigen is eliminated
but its down-regulation can be observed prior to antigen
clearance in the case of acute antigen exposure. By contrast, PD-1 expression maintains a high level in chronically stimulated antigen-specific T cells, which leads to
their functional exhaustion in response to stimuli [52].
Similar to other B7 proteins, PD-L1 and PD-L2 are
transmembrane glycoproteins [53]. Compared to PD-L2,
PD-L1 is expressed on a variety of normal and immune
cells including macrophages and DCs as well as cancer
cells after exposure to pro-inflammatory stimuli [31]. In
addition, PD-L2 is inducibly expressed in hematopoietic
cells including macrophages, DCs, mast cells, and certain
B cell populations [54, 55]. In the tumor microenvironment, PD-L1 expressed by cancer cells binds to its receptor PD-1 located on activated T cells on the tumor sites.
This interaction consequently triggers inhibitory signals
to the T cells and prevents the host immune system from
suppressing the growth of tumor [56].
The structure of PD-L1 includes an extracellular
domain followed by a transmembrane domain and an

a

intracytoplasmic region [53]. As shown in Fig. 1b, the
extracellular domain of PD-L1 consists of Ig variable distal and constant proximal regions. It is anchored to the
membrane by a hydrophobic transmembrane sequence.
The intracytoplasmic region consists of three conserved
sequences including RMLDVEKC and DTSSK motifs,
which are RNA pol-like motifs [57], and a QFEET motif.
The DTSSK motif is a negative regulator of the RMLDVEKC motif, which is responsible for suppressing the
phosphorylation of signal transducer and activator of
transcription 3 in tumor cells [57].
The underlying mechanisms of the PD-1 signaling
pathway are briefly summarized in Fig. 1a as PD-1 binds
to PD-L1 suppressing ZAP70 and PI3K phosphorylation
by recruiting Src homology 2 domain-containing protein
tyrosine phosphatase (SHP)1 and SHP2 phosphatases
to the ITSM and ITIM motifs in the intracellular tail
[58]. Consequently, the TCR signaling cascade is terminated [59]. SHP1 can bind to the ITIM and ITSM motifs,
whereas SHP2 preferentially binds to the ITSM [60, 61].
However, it is still unknown whether SHP1 and SHP2
compete to bind to the ITSM or both bind to the intracellular tail. The engagement of PD-L1 with PD-1 leads
to phosphorylation of ITSM and SHP-2 recruitment.
As a result, the phosphatidylinositol 3-kinase (PI3K)/
Akt signaling pathway is suppressed [62, 63]. PI3K/Akt
signaling pathway blockage further regulates a series of
downstream cellular events including the activation of
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Fig. 1 The signaling pathway of PD-1/PD-L1. a PD-L1 consists of an extracellular domain, a transmembrane domain, and an intracytoplasmic
region but lacks intracellular signaling. The intracytoplasmic region consists of three conserved sequences including RMLDVEKC, DTSSK, and QFEET
motifs. The part of the RMLDVEKC motif and the entire DTSSK motif that have been identified by MotifFinder are RNA pol-like motifs. b Antigens are
presented by APCs as antigenic peptides, which are recognized by the T-cell receptor (TCR; Signal 1). The second signal (Signal 2) is delivered when
B7 (CD80 and CD86) on the APCs engage CD28 on the T cells
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the mechanistic targets of rapamycin (mTOR), the activation of Bcl-Xl, the production of interleukin (IL)-2,
and the activation of nuclear factor-κB as well as inhibits
protein synthesis and cell growth. In addition, PI3K/Akt
signaling pathway blockage degrades transcription factor FoxO1, which binds to the promoter site of PD-1 and
increases its expression [31, 62].
The protein crystal structures of the PD-1/PD-L1 complex reveal that their interactions use large, hydrophobic
surfaces of the extracellular domains [53]. Within the
complex, PD-1 and PD-L1 are almost perpendicular to
each other, facilitating interactions through the majority
of the surface of their ‘‘front’’ strands. Currently, there are

three identified hotspots on PD-L1 (Fig. 2). Two of three
hotspots are regarded as drug binding pockets. The first
hotspot is a classic pocket with a hydrophobic domain,
which includes amino acid residues lTyr56, lGlu58,
lArg113, lMet115, and lTyr123. This hotspot has a
favorable size to accommodate an aromatic six-membered ring. The second hotspot with lMet115, lAla121,
and lTyr123 residues can be effectively occupied by a
branched aliphatic moiety, which can anchor with a terminal hydrogen bond donor moiety at the carbonyl oxygen of lAla121. The third hotspot is an extended groove
formed by the main chain and the side chains spanning
residues lAsp122 to lArg125, and is flanked by the side

a

PD-1

PD-L1

b
Comprised residues
LTyr56, LGlu58, LArg113, LTyr123,
LMet115, LAla121,

and LMet115

and LTyr123

LAsp122, LTyr123, LLys124, LArg124,

and LAsp126

Fig. 2 The structure of PD-L1 (4ZQK) and three main hot spots between PD-1 and PD-L1. a The structures of PD-L1 and PD-1. Amino acid residues
in the main hot spots are labeled as orange color. b Three main hot spots are exhibited. The first hotspot includes lTyr56, lGlu58, lArg113, lMet115,
and lTyr123. The second hotspot includes lMet115, lAla121, and lTyr123. The third hotspot is an extended groove formed by the main chain and
the side chains spanning residues lAsp122 to lArg125, and is flanked by the side chain of lAsp26
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chain of lAsp26. This hotspot can provide multiple
hydrogen bond donors/acceptors. However, it has a relatively shallow space, making it a difficult target for inhibitors of protein interactions.
Overall, it is challenging to target the interface of PD-1/
PD-L1 because of its large and flat hydrophobic pockets
(1970 A2) as compared to some other druggable proteins
with deep hydrophobic pockets [53]. One of the rational
designs for the discovery of PD-1/PD-L1 inhibitors is to
evaluate the interactions between the leading compounds
and these drug binding pockets using computational
based screening methods, which can be further validated
by in vitro and in vivo bioassays to eliminate false positive
“hits”.

Current methodologies for the development
of PD‑1/PD‑L1 inhibitors
Over the past decades, considerable research efforts have
been dedicated to the development of small molecule
inhibitors against PD-1/PD-L1 immune checkpoints
[64–66]. Biophysical and biochemical assays along with
cell-based assays have been developed to identify and
evaluate the binding affinity between these inhibitors and
PD-1/PD-L1, and their blockage effects toward PD-1/
PD-L1 interactions. A workflow for screening potential
inhibitors of PD-1/PD-L1 is shown in Fig. 3.
Binding affinity is one of the most critical parameters
to measure the capacity of potential inhibitors binding to
PD-1/PD-L1 proteins. PD-1/PD-L1 interactions can be
characterized by a series of methods summarized in this
review. These biophysical methods are usually performed
at the protein level. Although these methods may lead to
indefinite parameters regarding the dissociation constant
(KD) [53, 55, 67, 68], binding affinity measurement is still
usually required to identify small molecule inhibitors
against PD-1/PD-L1.

Surface plasmon resonance (SPR)

SPR is an optical biosensor technology based on the evanescent wave phenomenon to measure changes in the
refractive index of biosensor [69]. The light generated
by the light source hits the biosensor and prism. Analyte
flows through the channel and binds to the target protein, leading to a shift in the refractive index of the biosensor. The interactions between analyte and proteins
are monitored in a real-time manner and the amount of
bound proteins and rates of association and dissociation
are measured with high precision. SPR is widely used for
determining intermolecular interactions. PD-1/PD-L1
interactions are based on their extracellular domains
and their interactions include hydrophobic and polar
effects. Small molecule inhibitors with blockage effects
against PD-1/PD-L1 interactions bind to their extracellular interface. Therefore, SPR is an ideal tool to measure
the binding affinity between inhibitors and PD-1/PD-L1.
SPR can also determine the real-time kinetic constants
between inhibitors and PD-1/PD-L1, which requires the
immobilization of PD-1/PD-L1 protein on certain biosensors. His-tagged and tag-free PD-1/PD-L1 have been
widely immobilized on the biosensors using amine coupling methods [44, 65]. For instance, Yang and colleagues
developed an SPR technology-based screening method
that has successfully screened caffeoylquinic acids as
PD-1/PD-L1 inhibitors by immobilizing tag-free PD-1/
PD-L1 extracellular fragment on the CM5 biosensor
chip [65]. An advantage of SPR is that no modification
is required for the target proteins as compared to other
screening methods including NMR-based AIDA and
HTRF.
Biolayer interferometry (BLI)

BLI, similar to SPR, is a label-free technique monitoring real-time biomolecule interactions [70]. The working mechanism of BLI is similar to SPR as it detects

The Screening Workflow of PD-1/PD-L1 Inhibitors

Binding affinity
assay
Biophysical methods
including SPR, BLI,
ITC, MST, MDS,
DSF, FPIA, and
NMR to determine
binding parameters

Blockage ability
assay

Cell-based
Functional assay

Xenograft model
assay

Biochemical
methods
including ELISA and
AlphaLISA to
determine blockage
effects

Bioluminiscence
reporter cell-based
assay and T-cell
based assay to
evaluate biological
functions

Xenograft animal
model to investigate
the anti-tumor effects
and the underlying
mechanisms

Fig. 3 The screening workflow of PD-1/PD-L1 inhibitors. The identification of PD-1/PD-L1 inhibitors is required by using a series of assays including
binding affinity assay, blockage ability assay, cell-based functional assay and xenograft model assay
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the changes of the optical interference patterns on the
protein-coated biosensors that are generated by mass
changes from the interactions between analyte and protein [70]. Less protein is required for BLI measurement,
which facilitates high-throughput screening with great
potential to screen small molecule inhibitors against
PD-1/PD-L1. Unlike SPR which detects biomolecular
interactions under flow conditions, BLI is conducted
under non-flow conditions which impair its ability to
depict the kinetic profiles.
Isothermal titration calorimetry (ITC)

ITC is a useful method to characterize the thermodynamic parameters of interactions between analytes and
proteins [71]. The binding events are accompanied by
changes of enthalpy (∆H). Analyte-protein interactions
driving the process and parameters including stoichiometry of binding (n), the binding constant (Ka), K
 D,
∆H, and entropy (ΔS) can be determined. PD-1/PD-L1
interactions exhibit a favorable ΔHobs and TΔS and their
binding is driven entropically [53]. However, Pascolutti
and colleagues reported that the driving force of wildtype PD-1/PD-L1 exhibits an entropic component [72].
An advantage for ITC measurement is that it does not
require immobilization, protein modification, or fluorescent labeling. It is also an approach that can measure all
binding parameters in a single assay. However, ITC is not
suitable for high throughput screening due to being timeconsuming with high sample consumption.
Microscale thermophoresis (MST)

MST is a suitable technology for determining the intramolecular interactions with less sample consumption
[73]. MST is based on the directed movement of molecules along a microscopic temperature gradient [74].
Changes in their hydration shell, charge, or size can be
determined in this process. MST technology requires
two binding partners, one is labeled with fluorescence
dye and the other one is free-labeled [74]. MST does not
require immobilization. Intermolecular interactions can
be measured under physicochemical conditions or biological solutions. In addition, protein purification is also
not required to access the protein of interest [75]. However, the binding partner labeled with hydrophobic fluorescence may lead to non-specific binding. Consequently,
the bias of the results might be observed due to the indiscriminate fluorescent labeling.
MST is applied to determine PD-1/PD-L1 binding affinities [67] whereby cell lysate is extracted from
CHO-K1 cells that express PD-1-eGFP or PD-L1-eGFP,
to prepare the fluorescently labeled binding partner.
PD-L1 or PD-1 protein is used as label-free binding
partners. The KD value of 7.2 μM ± 1.9 μM between
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hPD-1 and hPD-L1-eGFP is obtained using MST [67],
which is similar to SPR assay (KD value of hPD-1/hPDL1 = 8.2 ± 0.1 μM) [53, 76]. Therefore, MST technology highlights its potential application for studying the
interactions between PD-1/PD-L1 and their inhibitors.
Differential scanning fluorometry (DSF)

DSF is an excellent screening assay to discover lowmolecular-weight ligands with binding affinities for
target proteins by monitoring the amount of the fluorescent dye that binds to the protein [77]. Ligand is
added into the solution containing protein and fluorescent dye in the polymerase chain reaction (PCR) microplates. Fluorescent intensities are measured as the
temperature is gradually raised by the PCR instrument
[78]. The binding of PD-1/PD-L1 inhibitors induces
thermal stabilization of PD-1/PD-L1, which is proportional to the inhibitors’ affinity [79]. DSF is suitable for
high-throughput screening due to the small amount
and low concentrations needed for protein binding.
However, impurities (e.g. detergent molecules) have to
be excluded from the reaction system. In addition, the
interactions between fluorescent dye and target proteins may interfere with the detection results. Recently,
it was reported that proteins that have already been
labeled with green fluorescent can be applied to avoid
the interactions with the fluorescent dye [80].
Fluorescence polarization immunoassay (FPIA)

FPIA is based on the principle of fluorescence anisotropy. As a homogenous assay, it determines the rotational and translational motion of excited fluorescent
molecules in the reaction mixture [81]. It is a rapid and
quantitative method to detect several biomolecular
interactions and enzyme activities. This assay is a feasible mix-and-read method with fewer reagents required,
which is suitable for high-throughput screening of peptides or nucleotide sequences binding to PD-1/PD-L1.
For instance, it has been successfully demonstrated that
FPIA can be applied to analyze the affinity between
self-inhibitory peptides (refers to peptides disrupting
the PD-1/PD-L1 complex formation) and PD-1 [82]. A
major disadvantage of FPIA is that the protein–protein
interactions containing extensive interfaces can lead to
low sensitivity for detecting biomolecules that are disproportionately important for the affinity of the interactions. In this case, competitive binding assays with
specific fluorescence polarization probes can be applied
to study the interactions between the molecules (e.g.
PD-1/PD-L1 inhibitor) and their featured interfaces
[83, 84].
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Nuclear magnetic resonance (NMR)

NMR is a powerful tool to determine the structure,
dynamics, and biomacromolecule interactions. NMR
can also detect the binding affinities of protein targets
with small molecules that have a broad affinity range
[85, 86]. It can detect weak intermolecular interactions,
which makes it a valid screening tool for low-affinity
fragments [86]. However, binary screening NMR does
not give information on whether the small molecules can
exert blockage effects on protein–protein interactions.
To overcome this limitation, Musielak and colleagues
described an NMR competitive assay, termed as weakantagonist induced dissociation assay-NMR (w-AIDANMR). In this competitive assay, lead compounds with
capacity of dissociating protein–protein interactions are
depicted by the strength of their binding affinities with
protein components involved in the protein–protein
interactions [85, 87]. The KD value of PD-1/PD-L1 complex is approximately 8 μM, which might be too strong
for the NMR-based screening for “weak” fragments, as
these fragments exhibit lower affinities with 2 to 3 orders
of magnitude. Therefore, instead of using PD-1, PD-1
mutant can be applied to estimate the K
 D value of fragments with PD-1/PD-L1. The KD values between fragments and PD-L1 by using w-AIDA-NMR method are
similar to the corresponding data from the HTRF assays,
supporting the reliability of the w-AIDA-NMR method.
In addition, some small molecule PD-L1 inhibitors that
block the PD-1/PD-L1 interactions have also been characterized using AIDA NMR [64, 88, 89]. Interestingly,
a combination of AIDA-NMR, PD-1/PD-L1 structurebased design, and fragment merging approaches creates
novel chemotypes as a starting point for the development of small molecule inhibitors against PD-1/PD-L1
[88]. Recently, high-field NMR spectrometers have been
developed to improve the NMR’s sensitivity and resolution [90], which highlights the potential application of
NMR-based methods in large-scale screening.
The enzyme‑linked immunosorbent assay (ELISA)
and alphaLISA

ELISA is a solid-phase type of enzyme immunoassay to
detect the presence of proteins using antibodies against
the proteins to be measured [91]. Because PD-L1 has
a strong binding affinity with PD-1, PD-1/PD-L1 pair
ELISA can be applied for screening small molecules
with blockage effects towards PD-1/PD-L1 interactions.
Briefly, PD-1 or PD-L1 protein (or PD-1/PD-L1 extracellular domain) is coated by incubation with biotin
labelled-PD-L1 or PD-1 with or without the small molecules of interest. Next, streptavidin–horseradish peroxidase and colorimetric horseradish peroxidase substrates
are added. The inhibitory abilities of small molecules
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towards PD-1/PD-L1 interactions are determined by
comparing the optical density values among the experimental groups. Although ELISA is a widely used detection platform for PD-1/PD-L1 inhibitors, it requires
multiple procedure steps (e.g. washes) with a relatively
narrow dynamic range (typically 2 logs). Therefore, more
than one sample dilution is required, which makes PD-1/
PD-L1 pair ELISA less feasible to adapt for high-throughput screening.
Alternatively, AlphaLISA is a homogeneous immunoassay that can be used to screen for PD-1/PD-L1 inhibitors in a high-throughput manner [92]. AlphaLISA is a
bead-based immunoassay without the requirement of
‘wash’. Therefore, it avoids washing times thereby reducing the total assay time as compared to ELISA. The principle of the AlphaLISA method is based on luminescent
oxygen-channeling chemistry. AlphaLISA consists of
donor beads and acceptor beads. Streptavidin-coated
donor beads are used to bind biotinylated-PD-L1, and
anti-His acceptor beads are used to bind to His-tagged
PD-1. Donor beads and acceptor beads interact with
each other due to the strong binding affinity between
PD-1 and PD-L1. Donor beads contain a photosensitizing agent that can be illuminated by a wavelength of
680 nm generating singlet oxygen, which initiates a cascade reaction with the acceptor beads. Consequently, the
acceptor beads will generate a remarkable signal amplification (at 615 nm) by singlet oxygen released from the
donor beads. Small sample volumes (1–5 μL) with high
sensitivity and wide dynamic ranges (typically 3 logs) are
required in the AlphaLISA assay. Therefore, it is an ideal
platform for high-throughput screening.
Bioluminescent reporter cell‑based assay

Bioluminescent reporter cell-based assay, which consists
of two engineered cell lines including PD-1 effector cell
line and PD-L1 aAPC/CHO-K1 cell line, can be used for
screening the PD-1/PD-L1 inhibitors [93]. PD-1 effector cell line is constructed on Jurkat T cell line that stably expresses PD-1 by transfection of luciferase reporter
plasmids containing NFAT response element. PD-L1
aAPC/CHO-K1 cell line is constructed on CHO-K1 cell
line that expresses PD-L1 by engineering cell surface
proteins to activate cognate TCRs without antigen. In
the co-culture system, PD-1 binds to PD-L1 and subsequently suppresses the TCR signaling and luminescence
mediated by NFAT response element. The presence of
PD-1/PD-L1 inhibitors blocks the PD-1/PD-L1 interactions, leading to the reactivation of TCR signaling and
luminescence. Quantification of TCR activation with or
without PD-1/PD-L1 inhibitors is measured by the intensity of luciferase activity. In addition, the NF-κB reporter
assay is an alternative option for the NFAT response
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element reporter system. However, it is preferable to use
the NFAT response element reporter system because
the NF-κB signaling is a less specific marker of the CD3
dependent T cell activation that can be activated by other
stimuli7 [94, 95].
Unlike the other aforementioned biophysical and biochemical assays that cannot evaluate the functional
impact of small molecules on PD-1/PD-L1 interactions,
bioluminescent reporter cell-based assay has an advantage of assessing the biological functions of PD-1/PD-L1
inhibitors by measuring the activation of NFAT signaling pathway. In addition, this commercialized assay
is a labor- and time-efficient tool, which is suitable for
high-throughput screening. Moreover, bioluminescent
reporter cell-based assay has less variation as compared
to primary cell-based assays [96]. However, the current
bioluminescent reporter cell-based assays cannot provide
information of antigen-specific or multiparametric interactions. Due to PD-1/PD-L1 mediated downstream signaling transductions involved in many proteins [31], the
bioluminescent reporter cell-based assay is insufficient to
evaluate the functions of PD-1/PD-L1 inhibitors on the
signaling transduction-related proteins.
T cell‑based assay

Although a cell-free assay system can be used to evaluate
the basic biological functions of PD-1/PD-L1 inhibitors,
further biological effects of leading inhibitors on PD-1/
PD-L1’s physiological properties, including their subcellular localization, or functional changes upon stimulation, might not be evaluated sufficiently with cell-free
assays alone. To evaluate the bioactivities and complicated physiological functions of PD-1/PD-L1 inhibitors,
T cell-based assays are often used.
T cell-based assays consist of effector cells expressing
PD-1, cells presenting PD-L1, and the activation signal
(CD3 activator) for effector cells. Several methods for the
development of inhibitors targeting PD-1/PD-L1 using T
cell-based assays have been reported [47]. The activation
of CD3 (Signal 1) is an essential step for the activation
of PD-1 effector cells in this assay. The TCR/CD3 can be
expressed by the effector cells and activated by several
biological components including peptide/MHC complex on the target cells, superantigen in the presence of
APCs expressing MHC II, soluble CD3ε antibodies, and
activator cells expressing transmembrane aCD3ε. In the
T cell-based assays, tumor cells or target cells expressing tumor-associated antigen are often used [97]. In
these assays, the presence of effector cells express tumorassociated antigen-specific CAR containing the CD3ζ
signaling domain, or TCR/CD3 effector cells with CD3
antibodies and tumor-associated antigen antibodies,
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leads to the dependent activation of CD3 in the effector
cells.
In the T cell-based assays, immobilized cell lines are
preferable to avoid issues with accuracy and reproducibility associated with primary cells [98, 99]. For instance,
the immobilized Jurkat human T cell line, a commonly
used T cell line, has been successfully developed to measure the CD3 dependent T cell activation [100]. In addition, the Jurkat human T cell line is suitable for genetic
engineering, which can be applied for evaluating the
biological effects of small molecules targeting PD-1. Versteven and colleagues developed an antigen-specific and
high-throughput T cell-based assay by using a genetically modified TCR-deficient Jurkat T cell line that is also
transduced with PD-1 plasmid [101].
T cell-based assays are widely used to evaluate the
blocking abilities and biological functions of PD-1/PD-L1
inhibitors [102]. Although the binding abilities of small
molecule inhibitors against PD-1/PD-L1 are usually analyzed by biophysical and biochemical assays, T cell-based
assays are also used to evaluate their blocking abilities
based on flow cytometry method [103]. To evaluate the
blocking abilities of PD-1/PD-L1 small molecule inhibitors, cell co-culture based assays or single-type cell incubated with PD-1 or PD-L1 proteins are often used. For
instance, small molecule inhibitors can be incubated in
a co-culture system with T cells expressing PD-1 and
APCs/tumor cells expressing PD-L1. The blocking abilities of small molecule inhibitors can be evaluated by
measuring PD-1/PD-L1 expression using flow cytometry
[104]. Similarly, in a single-type cell incubated with PD-1
or PD-L1 protein, the blocking affinity of small molecule
inhibitors against PD-1 or PD-L1 protein is measured by
the qualification of fluorescence intensity.
The primary aim for using T cell-based assay is to
verify the biological functions of PD-1/PD-L1 inhibitors. In the tumor microenvironment, overexpression
of PD-1 leads to T cell dysfunction, whereas PD-1/
PD-L1blockage reactivates T cell’s biological functions [105]. The functional assays need a co-culture
system consisting of PD-1 expressing cells and PD-L1
expressing cells. It is based on the change of T cell dysfunction in the presence of small molecules targeting
PD-1/PD-L1. The functional assays of T cells include
measurements of cell proliferation, T cell-related
cytokine release (IL-2 and interferon (IFN)-γ), and the
change of PD-1 downstream events including signaling
proteins and their phosphorylation [106]. For instance,
low proliferative capacity is a key character of T cell
dysfunction [54], and cell proliferation is one of the
most used assays to evaluate the biological functions
of PD-1/PD-L1 inhibitors. In addition, the detection of
IL-2 and IFN-γ are also widely used in the functional
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assay as IL-2 and IFN-γ are essential for T cell proliferation and activity, respectively [107, 108]. Furthermore, signaling proteins involved in the PD-1/PD-L1
axis-mediated signaling transductions can be investigated to evaluate the biological effects of PD-1/PD-L1
inhibitors.

Natural product‑derived PD‑1/PD‑L1 inhibitors
Most mAbs have inherent shortcomings including limited permeability, irAEs, immunogenicity, and high
cost, as compared to small molecules derived PD-1/
PD-L1 inhibitors [109, 110]. Small molecule inhibitors
usually have less side effects, shorter biological halflife, and are less expensive with easier administration
routes. Several published review articles have summarized the advantages of various synthetic small molecule PD-1/PD-L1 inhibitors [64, 66, 111]. Recently,
several natural product-derived small molecules with
blockage effects against PD-1/PD-L1 interactions have
been reported. Instead of elaborating on all current
small molecule inhibitors, herein we summarize natural product-derived PD-1/PD-L1 inhibitors with an
emphasis on the screening methodologies that were
applied for their identification.
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Macrocyclic compounds
Gramicidin derivatives from Bacillus brevis

Gramicidin S is a natural decacyclopeptide consisting
of two repeating pentapeptides as cyclo(-Val-Orn-LeuD-Phe-Pro-)2, which imposes a unique amphiphilic
structure with hydrophilic and hydrophobic residues on
the opposing side of cyclopeptide plane ring. Sun and
co-workers hypothesized that gramicidin S’s amphiphilic structure can be complementary to the interface of
PD-L1/PD-L1 thereby facilitating their binding capacity
[112]. An in vitro binding assay (HTRF) was determined
to evaluate the blockage efficacy of cyclopeptides towards
PD-L/PD-L1 binding and gramicidin S exhibited a weak
blockage efficacy of 6.86%. They further chemically synthesized a series of cyclopeptides using the skeleton of
gramicidin S [112]. Among the synthesized gramicidin S derivatives, Cyclo(-Leu-DTrp-Pro-Thr-Asp-LeuDPheLys(Dde)-Val-Arg (Fig. 4) exhibits the most potent
blockage efficacy of 95.8% at 20 µM against PD-1/PD-L1
interactions. It had the lowest IC50 value of 1.42 µM
against PD-1/PD-L1 interactions based on the co-immunoprecipitation assay. Co-administration of Cyclo(-LeuDTrp-Pro-Thr-Asp-Leu-DPheLys(Dde)-Val-Arg (40 mg/
kg) by intraperitoneally injection (ip) with anti-CD8 antibody suppressed the tumor volume (54.8%) and tumor

Fig. 4 Chemical structures of natural products based PD-1/PD-L1 inhibitors including cyclo(-Leu-DTrp-Pro-Thr-Asp-Leu-DPhe-Lys(Dde)-Val-Arg-),
rifabutin, kaempferol, kaempferol-7-O-rhamnoside, eriodictyol, fisetin, glyasperin C, cosmosiin, ellagic acid, and caffeoylquinic acids

Liu et al. Cancer Cell Int

(2021) 21:239

weight (64.9%) in a B16F10 tumor bearing animal model.
Immunohistochemistry staining showed that treatment
with Cyclo(-Leu-DTrp-Pro-Thr-Asp-Leu-DPheLys(Dde)Val-Arg enhanced the percentage of CD3+ T cells and
CD8+ T cells in the tumor tissues. In addition, the binding properties of the most promising cyclopeptide were
well characterized using a panel of biochemical, biophysical, and cell-based assays including SPR, Western
blotting (WB), NMR, circular dichroism (CD), co-immunoprecipitation, and molecular docking. The key findings
in this study are summarized in Table 1.
Ansamycin antibiotic

Patil et al. used an AlphaLISA assay to screen the
inhibitory effects of FDA-approved macrocyclic drugs
against PD-1/PD-L1 interactions [113]. A collection
of 20 macrocyclic compounds including actinomycin
D, amphotericin B, bacitracin, bryostatin, candicidin,
clarithromycin, cyclosporin A, cyanocobalamin, erythromycin, everolimus, geldanamycin, ivermectin B1a,
macbecin, metocurine, monocrotaline, nystatin, plerixafor, rifampin, sirolimus, and troleandomycin was
screened at a concentration of 50 µM using the AlphaLISA assay. Among these macrocyclics, only rifampin
(Fig. 4), an ansamycin type of antibiotic, effectively
blocked the interactions between PD-1 and PD-L1
(blockage efficacy = 47.9%) whereas the other compounds were less effective (blockage efficacy < 20%). Four
additional rifampin analogs including rifabutin, rifapentine, rifamycin SV, and 3-formyl rifamycin were selected
for further evaluation. Rifampin analogs (50 µM) showed
promising blockage efficacy ranging from 24 to 66.7%, in
which rifabutin was the most active macrocyclic antibiotic with an IC50 value of 25 µM (Table 1). In addition,
molecular docking demonstrated that rifabutin is able
to form a stable ligand–protein complex facilitated by
several molecular forces including π–π stacking interaction and hydrogen bonding. However, binding affinities
between these ansamycin antibiotics and PD-1/PD-L1
proteins are not reported.
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(Jurkat T/CHO-K1 cells) assay. The 
EC50 values of
kaempferol and kaempferol-7-O-rhamnoside were 16.46
and 15.37 μM, respectively, against PD-1/PD-L1 interactions in a dose-dependent manner. The direct binding
between kaempferol and PD-1 or PD-L1 were measured by obtaining the binding kinetics including the K
 D,
ka, and kd using BLI and SPR technologies. In addition,
a computational-based approach was used to map the
binding site of kaempferol and kaempferol-7-O-rhamnoside on PD-1 or PD-L1 and calculate the binding energy
between the ligands and proteins.
Apigenin and cosmosiin from Salvia plebeia

Choi et al. reported that Salvia plebeia R. Br. extract
(SPE) blocked the interactions between PD-1 and PD-L1
[115]. Two flavonoids including apigenin and cosmosiin
(Fig. 4) from SPE showed blockage effects against the
interactions between PD-1 and PD-L1 in a cell-based
assay (aAPC/CHO-K1 cells) and a competitive ELISA
assay. PD-L1 aAPC/CHO-K1 cell co-culture based assay
demonstrated that E
C50 values of SPE and SPE-ethyl
acetate fraction were 27.2 mg/mL and 1.08 mg/mL,
respectively, against PD-1/PD-L1 interactions. In addition, cosmosiin, identified as the strongest PD-1/PD-L1
inhibitor among 7 SPE fractions, was able to directly bind
to PD-1 and PD-L1 with a K
 D value of 386 and 85 µM,
respectively, in the BLI assay. Computational docking was
then determined to predict cosmosiin’s binding capacity to PD-1 and PD-L1, showing a binding energy of -6.2
and -5.8 kcal/mol, respectively (Table 1). Moreover, the
inhibitory effect of SPE on PD-1 and PD-L1 was further
supported by in vivo assays using a humanized PD-L1
knock-in MC38 tumor-bearing animal model. Treatment
of SPE at doses of 100 and 300 mg/kg exhibited tumor
inhibition rates of 44.9 and 77.8%, respectively, in a dosedependent manner on day 16. In addition, treatment of
SPE (300 mg/kg) enhanced the infiltration of CD8+ T
cells in the tumor tissues.
Eriodictyol and fisetin from Rhus verniciflua Stokes extract

Phenolic compounds
Kaempferol and kaempferol‑7‑O‑rhamnoside

Kaempferol and its glycosides including kaempferol3,7-dirhamnoside and kaempferol-7-O-rhamnoside, are
flavonoids from Geranium thunbergia (Geranii Herba
extract) with reported antitumor activities [114]. In vitro
assays were used to demonstrate that kaempferol and
kaempferol-7-O-rhamnoside are able to block PD-1/
PD-L1 interactions. Competitive ELISA assays were
used to measure the inhibitory effects of kaempferol and
kaempferol-7-O-rhamnoside (Fig. 4) on the PD-1/PD-L1
interactions, which were supported by cell co-culture

Li and colleagues screened 800 herbal extracts for the
PD-1/PD-L1 inhibition capacity, which led to the identification of Rhus verniciflua Stokes extract as an active
inhibitor using competitive ELISA [116]. Four phenolic
compounds including eriodictyol, fisetin, quercetin, and
liquiritigenin were isolated from the Rhus verniciflua
Stokes extract with PD-1/PD-L1 blocking effect. Eriodictyol and fisetin showed the most potent inhibitory
effect in the competitive ELISA with an IC50 value of 0.04
and 0.4 µM, respectively. However, the binding affinity
between eriodictyol or fisetin and PD-1/PD-L1 was not
reported.
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Table 1 A summarize of natural product-derived PD-1/PD-L1 inhibitors
Natural products
Name

Type

Sub-type

Amphotericin B

Macrocyclic

Macrolide

Bacitracin

Cyclic peptide

Everolimus

Macrolide

Clarithromycin

Macrolide

Cyclosporin A

Cyclic peptide

Actinomycin D

Cyclic peptide

Cynocobalamin

Porphyrin

Bryostatin

Macrolide

Candicidin

Macrolide

Geldanamycin

Polyketide

Ivermectin B1a

Macrolide

Macbecin

Ansamycin

Metocurine

Alkaloid

Monocrotaline

Alkaloid

Nystatin

Macrolide

Plerixafor

Bicyclam

Sirolimus

Macrolide

Troleandomycin

Macrolide

Rifampin

Ansamycin

Methodology

Key finding(s)

AlphaLISA; MD

Not active

Weak PD1/PD-L1 inhibitor (less than 20% inhibition at
50 µM)

PD1/PD-L1 inhibition was 47.9% at 50 µM

Rifabutin

PD1/PD-L1 inhibition was 66.7% at 50 µM
IC50 was 25 µM

Rifapentine

PD1/PD-L1 inhibition was 52.1% at 50 µM

Rifamycin SV

PD1/PD-L1 inhibition was 34.5% at 50 µM

Formyl rifamycin

PD1/PD-L1 inhibition was 40.2% at 50 µM

Rifaximin
Gramicidin S

PD1/PD-L1 inhibition was 24.0% at 50 µM
Macrocyclic

Cyclic peptide

HTRF; NMR; SPR; CD; MD PD1/PD-L1 inhibition was 6.86% at 20 µM

Gramicidin S derivative

Kaempferol

PD1/PD-L1 inhibition was 95.8% at 20 µM; IC50 was
1.42 µM
Conserved the β-sheet conformation of the gramicidin
S skeleton
KD was 1.66 mM and 5.67 µM for PD-1 and PD-L1,
respectively
Phenolic

Kaempferol-7-O-rhamnoside

Cosmosiin

Phenolic

Flavonoid

Flavanone

ELISA; BLI
Cell based assay
MD

Isoflavan

Increased T-cell functional activity by 1.91-fold; Had
KD value of 386 and 85 µM for PD-1 and PD-L1,
respectively
Fit to a 1:1 binding model to PD-1 and PD-L1; Had a
predicted binding affinity of − 6.2 and − 5.8 kcal/mol
for PD-1 and PD-L1, respectively
Increased T-cell functional activity by 2.03-fold

ELISA

Flavonol
Phenolic

IC50 for blocking PD-1/PD-L1 was 7.797 µM
Cellular PD-1/PD-L1inhibition IC50 was 14.46 µM
Calculated binding energy was -5.4 and -5.0 kcal/mol
for PD-1 and PD-L1, respectively
Cellular PD-1/PD-L1inhibition IC50 was 14.46 µM
KD was 31.1 and 19.7 µM for PD-1 and PD-L1, respectively
Calculated binding energy was -5.6 and -5.3 kcal/mol
for PD-1 and PD-L1, respectively

Flavonoid
Phenolic

Fisetin
Glyasperin C

ELISA; BLI; SPR
Cell based assay
MD

Flavonoid

Apigenin
Eriodictyol

Flavonoid

Had an IC50 of 0.04 µM for PD-1/PD-L1
Had an IC50 of 0.04 µM for PD-1/PD-L1

HTRF

Had an PD-1/PD-L1 inhibition rate of 64.3% at 100 µM
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Table 1 (continued)
Natural products
Name

Type

Sub-type

Caffeoylquinic acid

Phenolic

–

3-O-caffeoylquinic acid

Caffeoylquinic acid

4-O-caffeoylquinic acid

Caffeoylquinic acid

5-O-caffeoylquinic acid

Caffeoylquinic acid

Key finding(s)

SPR

KD = 1.24 × 10−5 M for PD-1; not detected for PD-L1

KD = 1.95 × 10−6 M for PD-1; 1.71 × 10−5 M for PD-L1

KD = 5.07 × 10−6 M for PD-1; not detected for PD-L1

Ellagic acid

Phenolic

ZINC 67,902,090

Heterocyclic Pyrrolidine-oxadiazole AlphaLISA
WB
MD

ZINC 12,529,904

–

Methodology

ELISA
WB
Cell based assay

KD = 1.68 × 10−5 M for PD-1; 8.13 × 10−5 M for PD-L1

Blocked PD-1/PD-L1 binding with an IC50 value of
22.92 μg/mL
Bound to PD-1 and PD-L1 in WB;

PD-1/PD-L1 inhibition potency was 30% as compared
to BMS-202
PD-1/PD-L1 inhibition potency was 40% as compared
to BMS-202

Glyasperin C from Glycyrrhiza uralensis

Caffeoylquinic acid derivatives

Bao et al. reported the isolation of a flavonoid, glyasperin C (Fig. 4), from Glycyrrhiza uralensis and its
PD-1/PD-L1 inhibitory effect using a commercially
available homogeneous time resolved fluorescence
(HTRF) assay [117]. The isolated compounds showed
PD-1/PD-L1 inhibition ratios ranging from 30 to 65%
at 100 µM.

Caffeoylquinic acid and its derivatives (Fig. 4) with a
caffeoyl group attached to the − 3, − 4, and − 5 position of quinic acid, respectively, were identified as PD-1/
PD-L1 inhibitors using SPR spectroscopic method [65].
The KD values of caffeoylquinic acid and its derivatives on PD-1 and PD-L1, ranged from 0.507 × 10–5 to
1.68 × 10–5 M and from 1.71 × 10–5 to 8.13 × 10–5 M,
respectively, as determined by SPR (Table 1). In addition,
a competitive SPR assay was used to compare the binding capacity between quinic acid derivatives with one or
two caffeoyl group(s) and PD-1. It was concluded that, as
compared to dicaffeoylquinic acids, mono-caffeoylquinic
acid derivatives had a stronger binding affinity with PD-1
and PD-L1.

Ellagic acid from black raspberry (Rubus coreanus Miquel)
extract

Kim et al. reported that a black raspberry (Rubus coreanus Miquel) extract (RCE) interrupted the binding
of PD-1 and PD-L1 with an IC50 value of 83.8 ± 4.7 μg/
mL in the competitive ELISA assay [118]. PD-L1 aAPC/
CHO-K1 cell co-culture based assay revealed that RCE
increased the production of IL-2 by 1.8-fold with an E
 C50
value of 56.15 ± 14.35 μg/mL, as compared to the control group. The inhibitory effect of RCE on PD-1/PD-L1
interaction was further supported by in vivo data using
a humanized PD-L1 knock-in MC38 tumor-bearing
animal model, in which oral administration of RCE (50
and 100 mg/kg/day) exhibited tumor inhibition rates of
66.94% and 73.81%, respectively, on day 21. In addition,
the major phytochemical in RCE was identified as ellagic
acid (Fig. 4) and its effects on PD-1 and PD-L2 interaction were evaluated using in vitro assays including competitive ELISA, WB pull-down, and cell-based assays
(PD-1 Jurkat effector cell/ PD-L1 CHO-K1 cell). Ellagic
acid was shown to block PD-1/PD-L1 interaction in a
concentration-dependent manner with an IC50 value of
22.92 μg/mL (Table 1). In addition, ellagic acid-conjugated sepharose 4B beads pull-down assay showed that
ellagic acid was able to directly bind PD-1 and PD-L1 and
interrupt their binding capacity [118].

Heterocyclic compounds

Several heterocyclic compounds containing nitrogen atoms have been reported to show blockage
effects against PD-1/PD-L1 interactions. Using in silico virtual screening methods, Lung et al. reported
that two pyrrolidine-oxadiazole derivatives including
(3S,3aR,6S,6aR)-N6-[4-(3-fluorophenyl)-pyrimidin-2-yl]N3-(2-pyridylmethyl)-2,3,3a,5,6,6a-hexahydrofu (ZINC
ID#67902090) and 1-isopropyl-3-[(3S,5S)-1-methyl-5-[3(2-naphthyl)-1,2,4-oxadiazol-5-yl]pyrrolidin-3-yl]urea
(ZINC ID#12529904) were identified as PD-1/PD-L1
inhibitors among 180,000 natural compounds from the
ZINC12 database [119]. The inhibitory effects of ZINC
67,902,090 and 12,529,904 were evaluated by the AlphaLISA binding and PD-L1 dimer formation assays. AlphaLISA binding assays demonstrated that ZINC 67,902,090
and 12,529,904 have the potencies of 30 to 40% for
inhibiting the PD-1/PD-L1 interaction, as compared to
BMS-202 (100%). PD-L1 dimer formation assay showed
that ZINC12529904 significantly promoted the amount
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assays are powerful for screening the promising "hits" and
for characterizing the binding parameters between identified "hits" and PD-1/PD-L1. Assays including ELISA,
alphaLISA, bioluminescent reporter cell-based assays,
and T-cell based assays are crucial to eliminate false positive “hits” as well as evaluate their biological functions.
A rational workflow was established for screening PD-1/
PD-L1 inhibitors (Fig. 5a). SPR technology was performed to evaluate binding affinities between small molecule and PD-L1. The identified PD-L1 inhibitors were
selected for PD-1/PD-L1 pair ELISA assay. Once the
inhibitors exert blockage effects on PD-1/PD-L1 interactions, bioluminescence reporter cell-based assay can
be applied for determining their biological functions.
The identified PD-L1 inhibitor without blockage effects
on PD-1/PD-L1 interactions is a "false" positive hit. For
instance, punicalagin (PA) is an ellagitannin found in
pomegranate (Punica granatum). Our screening data
demonstrated that PA exhibits a stronger binding affinity
with PD-L1 than BMS-1166, a positive PD-L1 inhibitor
(Fig. 4b). The K
 D value of 5.5 × 10–10 M is determined by
SPR. Notably, the PD-1/PD-L1 pair ELISA demonstrated
that PA only showed minor blockage effects against
PD-1/PD-L1 interactions (Fig. 5b). As discussed, biophysical methods, such as SPR, provides binding parameters of identified inhibitor with PD-1 and/or PD-L1.

of PD-L1 dimer, whilst ZINC 67,902,090 only slightly
increased the amount of PD-L1 dimer. The binding mode
of these two compounds was supported by the molecular
docking study but their direct binding affinities were not
investigated.

Perspective
In 2018, the Nobel Prize in Physiology or Medicine was
awarded to James Allison and Tasuku Honjo for their discovery of immune checkpoint therapy [120, 121]. PD-1
functions as a T-cell brake and the activation of PD-1/
PD-L1 suppresses T cell’s proliferation, survival, and
activity in the tumor microenvironment [31]. Clinical
studies supported that PD-1/PD-L1 blockage can effectively introduce durable antitumor immune responses
with less toxicity in many types of cancers [16]. Currently, the majority of approved PD-1/PD-L1 inhibitors
are mAbs [16, 109] while the development of small molecule inhibitors directly blocking PD-1/PD-L1 interactions is still in the stage of infancy.
Over the past decade, with a more advanced understanding of PD-1/PD-L1 interactions and the underlying mechanisms, there has been an explosion of interest
in the development of bioassays that can be applied for
screening small molecule inhibitors against PD-1/PD-L1
[64, 88, 101, 102, 104]. Biophysical and biochemical
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Bioluminescence reporter
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Fig. 5 A workflow was established for screening PD-1/PD-L1 inhibitors. a SPR technology was performed to evaluate binding affinities followed by
PD-1/PD-L1 pair ELISA assay. Once the inhibitors exert blockage effects on PD-1/PD-L1 interactions, bioluminescence reporter cell-based assay will
be applied for determining their biological functions. b The binding and inhibitory effects of Punicalagin (PA) and BMS1166 against human PD-L1
protein assessed using SPR and PD-1/PD-L1 pair ELISA assays, respectively. PA or BMS1166 was allowed to flow over Fc-PD-L1 captured on a flow
cell as well as on a reference cell of Series S Sensor Chip
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However, PA might not exert blockage effects towards
PD-1/PD-L1 even if it has strong binding affinities with
PD-L1. Future studies with in vivo models are warranted
to confirm this.
As summarized, the PD-1/PD-L1 interface is challenging to target because of its large and flat hydrophobic interface. Binding parameters need to be measured
for the small molecules and PD-1/PD-L1 interactions
including the ones at their interactive interface and other
non-interactive sites. Therefore, it is important to properly apply complementary approaches including biophysical, biochemical, and cell-based assays to achieve
robust measurements. These combination strategies are
critical to eliminate false positive “hits” (such as PA as
demonstrated in this review), which may only have binding capacity without blockage effects on PD-1/PD-L1
interaction. Nevertheless, we believe that more versatile
and advanced bioassays can be developed in the future
to shed more light on the discovery of PD-1/PD-L1
inhibitors.
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